Investor demand for exchange-traded funds is not slowing down, and firms without ETF offerings may risk losing business, according to one Goldman Sachs expert.
Steve Sachs, global chief operating officer of Goldman’s ETF Accelerator, notes that despite the time and resources required to launch an ETF, not offering current and new investment strategies as ETFs may prove even more costly.
“Any number of our clients would tell you, the opportunity cost of not [offering ETF products] is greater,” he recently told CNBC’s “ETF Edge.”
If a firm does not have ETF offerings, Sachs thinks “eventually those assets are going to leave and go to a competitor that does.”
To help clients through the process of launching their own ETF products, Goldman Sachs created its ETF Accelerator, a digital platform that helps clients launch, list and manage their own ETF products. The accelerator launched in 2022 in response to what Sachs described as significant client demand.
“Our core institutional clients were calling and asking, ‘How do we get into this ETF space? How do we deliver our strategy, active and otherwise, in an ETF wrapper?'” he said.
According to Sachs, client inquiries about launching ETFs surged following the passage of SEC Rule 6c-11 in 2019, which intended to help these funds launch more efficiently.
“While we wouldn’t call that a big boom, it was certainly a catalyst. The idea was it made it easier to launch an ETF, but it didn’t make it easy,” Sachs said. “At one point, we had more than 41 clients that had called us with exactly the same problem: ‘How do I do this, how do I move quickly and can you help us?'”
It can still take years to build the expertise, headcount and risk management framework necessary to launch an ETF, said Sachs. That is where Goldman’s accelerator platform aims to help.
“[It] allows our clients to come in, launch, list and manage their own ETF — but do it off of the technology, infrastructure and risk management expertise that Goldman’s known for and essentially get to market faster and cheaper than they could do it on their own,” Sachs said.
“GMO, Brandes [and] Eagle Capital all felt that the journey to build it on their own would be too expensive and too long,” Sachs said. “They didn’t want to miss the opportunity cost of not delivering their investment strategies in the wrapper.”
Investor Steve Eisman of “The Big Short” fame thinks it’s dangerous to chase upside right now. “I have one concern, and that’s tariffs. That’s it,” the former Neuberger Berman senior portfolio manager told CNBC’s ” Fast Money ” on Monday. “The market has gotten pretty complacent about it.” Now podcast host of “The Real Eisman Playbook,” Eisman contends Wall Street is underestimating the complexity of ongoing U.S. trade negotiations with China and Europe. “I just don’t know how to handicap this because there’s just too many balls in the air,” said Eisman, who warns a full-blown trade war isn’t off the table . It appears Wall Street shrugged off tariff risks on Monday. Stocks started the month higher — with the Dow Industrials coming back from a 416-point deficit earlier in the session. The tech-heavy Nasdaq Composite also rebounded from earlier losses and gained 0.7%. Eisman, who’s known for successfully shorting the housing market ahead of the 2008 financial crisis, is still invested in the market despite his concern. “I am long only. I’ve taken some risk down, and I’m just sitting pat,” he added. Meanwhile, Eisman is downplaying risks tied to balancing the massive U.S. budget deficit . From ‘ridiculous’ to ‘absurd’ “If there was an alternative to Treasurys, I might be worried more about the deficit because I’d say if we don’t balance our budget, then people will sell our Treasurys and buy something else,” Eisman said. “But what else are they going to buy? They’re not going to buy bitcoin . It’s not big enough. They’re not going to buy Chinese bonds. That’s ridiculous. They’re not going to buy European or Italian bonds. That’s absurd.” He’s also not worried about firming U.S. Treasury yields. “The 10-year [Treasury note yield] has gone up, but it’s still 4.5%,” said Eisman. “It’s not like there’s some crazy sell-off.” The benchmark yield was at roughly 4.4% as of Monday night. What about the prospect of the 10-year yield topping 5%? “Relative to where it’s been because rates were zero, it’s high,” Eisman said. “But relative to history, it’s not that high.” Sign up for the Spotlight newsletter, a hand-curated collection of video clips selected by CNBC’s top editors and producers. Your daily recap of top business highlights and leading stories. Disclaimer
Check out the companies making headlines in midday trading. Tesla — Shares of the electric vehicle company dropped 3% after sales in May in declined in several European markets. Reuters reported that Tesla suffered weaker sales in Sweden, France, Spain, Denmark and the Netherlands, but improved in Norway, boosted by the revamped Model Y. Advertising stocks — Advertising stocks were lower Monday following a report in the Wall Street Journal that Meta Platforms plans to use artificial intelligence to fully automate its ads by the end of the year. Shares of Omnicom Group lost 4%, while WPP Group and Interpublic shed 2% each. Steel stocks — Steel stocks were higher after President Donald Trump doubled tariff rates on imports to 50%. Cleveland-Cliffs soared more than 24%, while Nucor and Steel Dynamics each climbed 10%. Blueprint Medicines — Shares surged 26% after the biopharmaceutical company agreed to be acquired by Sanofi for $129 per share in a deal worth approximately $9.5 billion. Shares of Sanofi were fractionally lower. Sports betting stocks — Online sports betting stocks took a hit after Illinois lawmakers passed a budget that included a tax hike. DraftKings dropped more than 5%, while Flutter Entertainment and Rush Street Interactive slipped more than 3% and 1%, respectively. The Roundhill Sports Betting & iGaming ETF (BETZ) fell 1.6%. Auto stocks — Shares of automakers slipped after President Trump doubled tariffs on steel. General Motors and Ford tumbled nearly 5%, while Stellantis shed 3.5%. BioNTech — Shares advanced 18% on a multibillion-dollar deal with Bristol Myers Squibb to partner and co-develop an experimental cancer drug. The deal includes an upfront payment of $1.5 billion. Applied Digital — The digital infrastructure company’s shares soared more than 40% after entering two 15-year lease agreements with CoreWeave , a cloud services provider backed by Nvidia . Applied Digital expects to generate $7 billion in total revenue from the leases over the 15-year term. Coreweave jumped about 6% on the news. — CNBC’s Alex Harring, Yun Li, Michelle Fox, Lisa Kailai Han and Jesse Pound contributed reporting